News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AbbVie (ABBV) has received European Commission approval for its drug RINVOQ (upadacitinib) for new indications in the EU. RINVOQ is now approved as the first systemic treatment for non-segmental vitiligo and as a systemic option for severe alopecia areata in adults and adolescents. These …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%This article first appeared on GuruFocus. Release Date: July 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points AbbVie Inc (NYSE:ABBV) delivered another excellent quarter with total net revenues of nearly $17 billion, …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%This article provides a comprehensive stock analysis of Avient Corp (AVNT) by TradingKey, highlighting its healthy fundamentals, high growth potential, and fair valuation within the Chemicals industry. Despite recent weak stock market performance, the company shows strong fundamentals and is considered suitable for range-bound …
This article provides a technical analysis of Grupo Supervielle SA (SUPV), detailing its current price momentum score, support and resistance levels, and key technical indicators. The stock is currently trading between resistance at 10.25 and support at 8.85, making it suitable for range-bound swing …
This article provides an analysis of Navient Corporation (NASDAQ: NAVI) using AI-generated signals and institutional trading strategies. Key findings include strong near and mid-term sentiment but a weak long-term outlook, with a significant risk-reward short setup. The analysis offers specific entry, target, and stop-loss …
AbbVie slashes its full-year guidance to account for its pending acquisition of Apogee Therapeutics. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie ABBV reported second-quarter 2026 adjusted EPS of $3.65, which beat the Zacks Consensus Estimate of $3.64. The reported figure also exceeded the company's guidance of $3.57-$3.61 per share, issued earlier in July 2026. Earnings rose 22.9% year over year. ABBV's revenues of $16.99 …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%The article focuses on the "Enterprise value to EBIT forward" metric for Viemed Healthcare, Inc. (NASDAQ: VMD). It is a financial data point presented on TradingView, indicating the company's valuation relative to its future earnings before interest and taxes.
This article first appeared on GuruFocus. AbbVie (NYSE:ABBV) fell 3.46% premarket after trimming full-year guidance alongside second-quarter results that beat on both lines. Net revenues rose 10.2% to $16.99 billion against the $16.78 billion analysts expected, and adjusted diluted earnings of $3.65 a share …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie (NYSE: ABBV) shares fell after the company trimmed its full-year earnings guidance, despite reporting strong second-quarter earnings and revenue beats. The guidance reduction is primarily attributed to the anticipated acquisition of Apogee Therapeutics, which is expected to negatively impact 2026 earnings, although underlying …
For the quarter ended June 2026, AbbVie (ABBV) reported revenue of $16.99 billion, up 10.2% over the same period last year. EPS came in at $3.65, compared to $2.97 in the year-ago quarter. The reported revenue represents a surprise of +1.07% over the Zacks …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie beat second-quarter profit estimates due to strong immunology sales but announced a cut in its full-year adjusted earnings forecast by 14 cents per share. This reduction is attributed to the planned acquisition of Apogee Therapeutics for approximately $10.9 billion. The stock subsequently dropped …
AbbVie's (NYSE:ABBV) Q2 CY2026: Beats On Revenue Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts' consensus estimates. Is now …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate. Adjusted earnings per share came in at $3.65, missing analyst estimates of $3.71, while revenue of $16.99 billion exceeded the consensus …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie slightly reduced its 2026 profit forecast due to its planned acquisition of Apogee Therapeutics, which is expected to cut full-year earnings by 4 cents per share. Despite this, the company exceeded second-quarter estimates with strong immunology drug sales from Skyrizi and Rinvoq, counteracting …
AbbVie Inc. exceeded Wall Street's second-quarter profit and sales expectations, driven by robust performance in its immunology and neuroscience divisions. The company's top-selling drugs, including the wrinkle-smoothing injection Botox, outperformed forecasts, with Botox sales showing improvement for the third consecutive quarter. Adjusted earnings also …
Riverview Bancorp (NASDAQ:RVSB) recently surpassed analyst expectations for its first-quarter earnings, reporting EPS of US$0.08, beating predictions by 14%. While revenues of US$15 million were in line, the sole analyst covering the company has slightly downgraded future EPS forecasts but increased the price target …
Viemed Healthcare, Inc. (VMD) is expected to announce its Q2'26 earnings on August 3rd, with an estimated EPS of $0.12 and revenue of $78.00 million. This article provides a comparative table of reported and estimated revenue and EPS figures for recent quarters, highlighting surprises.
Navient Corp (NAVI) currently holds a weak financial score of 4.75, ranking low in the Banking Services industry due to low operating efficiency. The company reported a significant year-over-year decrease in quarterly revenue by 12.55% and a net profit decline of 950.00%. Key financial …
This article provides a risk assessment for Avient Corp (AVNT), detailing its volatility, financial, and investment risks. The company's current risk assessment score is 7.94, ranking 19 out of 65 in the Chemicals industry, and its beta value of 1.30 indicates higher volatility compared …
This article focuses on the enterprise value to EBIT forward data for Avient Corporation (NYSE: AVNT). It is a financial data point available on TradingView, serving as a resource for investors interested in the company's valuation metrics within the Chemicals: Major Diversified industry. The …
AbbVie Inc. (ABBV) shares declined by 2.24% to $257.41, breaking a two-day winning streak, despite an overall positive trading day for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains on Thursday. This report highlights AbbVie's performance …
This article provides a risk assessment for Highview Merger Ord Shs Class A (HVMC), focusing on various risk metrics. It includes data points such as Beta vs S&P 500 index, Maximum Drawdown, Realised Volatility, and Liquidity. The report details several financial indicators for different …
This article first appeared on GuruFocus. Revenue: 22.93 billion, up 1.5% at constant scope and forex (excluding energy prices). EBITDA: 3.552 billion, up 5% at constant scope and forex. EBITDA Margin: 16.0%, an increase of 70 basis points. Current Net Income: Up 10.4% at …
Sharemaestro market context Trend signal active 52 weeks +16.9% · Next-week setup positive 58.3%What To Expect From AbbVie's (ABBV) Q2 Earnings Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here's what to look for. AbbVie beat analysts' revenue expectations last quarter, reporting revenues of $15 billion, up 12.4% year on year. …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Navient (NAVI) is expected to report a year-over-year decline in Q2 earnings and revenues. The consensus EPS estimate has been revised 18.16% lower, and the stock currently has an Earnings ESP of -6.76% and a Zacks Rank of #3, making an earnings beat difficult …
Sharemaestro market context Price below Trend Line 52 weeks +0.8%Improved 2026 guidance A new semester of excellent performance, with +70bps EBITDA margin improvement and +10.4%(1) progression of current net income(2) Veolia is standing out in a volatile macro and geopolitical environment, with continuously improving results, thanks to solid operational execution and unique combination …
Sharemaestro market context Trend signal active 52 weeks +16.9% · Next-week setup positive 58.3%AbbVie's Allergan Aesthetics announced the fourth annual JUVÉDERM® Day will occur on August 19, 2026, coinciding with the 20th anniversary of the brand's first U.S. FDA dermal filler approval. Allē members can access a buy-one-get-one $75 JUVÉDERM® gift card promotion and double Allē points …
NEW ALBANY, Ohio, July 30, 2026--(BUSINESS WIRE)--Veolia, a global leader in environmental services, has been selected by a major project developer to operate and maintain a 350-megawatt microgrid to power an AI data center campus. This contract builds on Veolia's Data Center Resource 360 …
Sharemaestro market context Trend signal active 52 weeks +16.9% · Next-week setup positive 58.3%Allergan Aesthetics celebrates fourth annual JUVÉDERM®Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approval Join Allē today to take advantage of limited …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Search by ticker symbol or company name and select a result to open its chart.